EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review

Paul Saultier, Michel Grino, Céline Falaise, Sophie Voisin, Cécile Lavenu-Bombled, Manal Ibrahim-Kosta, Audrey Petit, Hélène Boutroux, Dominique Desprez iD, Mathieu Fiore iD, Roseline d'Oiron iD, Marie-Christine Alessi iD

Haemophilia · 2025

DOI: 10.1111/hae.15130 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Haemophilia, 2025. Verfasst von Paul Saultier und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology, Immunology and Oncology, Aix Marseille Univ, APHM, INSERM, INRAe, C2VN, La Timone Children's Hospital, Marseille,…. Hauptthemen laut MEDLINE: Thrombasthenia, Factor VIIa. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Platelet transfusion is considered the standard treatment for preventing or controlling severe haemorrhage in Glanzmann thrombasthenia (GT). However, platelet transfusion can have detrimental effects, including the production of anti‐GPIIb/IIIa isoantibodies or anti‐HLA antibodies (Ab) and platelet transfusion refractoriness. Recombinant activated factor VII (rFVIIa) has been proposed as an alternative treatment to platelet transfusion.

Methods

We analyzed data from 77 case reports including 100 subjects to investigate the effectiveness and safety of rFVIIa in combination with platelets or antifibrinolytics for preventing or treating non‐surgical bleeds, as well as surgical and obstetrical procedures in GT.

Results

The dosage of rFVIIa was consistent with previous recommendations (90 µg/kg per infusion). In subjects without Ab/refractoriness ( n = 56), rFVIIa was effective in managing 93% of non‐surgical bleeds ( n = 42), 91% of minor ( n = 11) and 92% of major ( n = 26) surgical procedures and 89% of obstetrical procedures ( n = 9). In subjects with Ab/refractoriness ( n = 44), rFVIIa was effective in managing 90% of non‐surgical bleeds ( n = 39), and 75% of minor ( n = 12) and 100% of major ( n = 17) surgical procedures. The use of rFVIIa was safe, with 4 (2.7%) serious adverse events associated with rFVIIa.

Conclusion

Although the use of rFVIIa is currently restricted to subjects with Ab/refractoriness or when platelets are not available, our findings suggest expanding the indications for rFVIIa to encompass GT without Ab/refractoriness. Frontline use of rFVIIa may be proposed when clinically possible to mitigate the risks associated with platelet transfusion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombastheniaFactor VIIaHumansRecombinant ProteinsHemorrhageFemalePlatelet TransfusionTreatment Outcome

Stichwörter der Autor:innen

Glanzmann thrombastheniaantifibrinolyticsantiplatelet antibodiesplatelet refractorinessplatelet transfusionrFVIIa

Substanzen

Factor VIIaRecombinant Proteinsrecombinant FVIIa

Autor:innen und Institutionen

  • Department of Pediatric Hematology, Immunology and Oncology, Aix Marseille Univ, APHM, INSERM, INRAe, C2VN, La Timone Children's Hospital, Marseille, France.
  • Reference Center for Inherited Platelet Disorders, Aix Marseille Univ, APHM, INSERM, INRAe, C2VN, Marseille, France.
  • Reference Center of Platelet Disorders, Department of Pediatric Hematology, Immunology and Oncology, APHM, Marseille, France.
  • Hematology Laboratory, Reference Center for Inherited Platelet Disorders, Toulouse University Hospital, Toulouse, France.
  • Department of Hematology, APHP, INSERM, Hemostasis, HITh, U1176, Resource and Competence Center for Constitutional Hemorrhagic Disorders, University of Paris-Saclay, Bicêtre Hospital, Le Kremlin-Bicêtre, France.
  • Hematology Laboratory, Reference Center for Inherited Platelet Disorders, Aix-Marseille Univ, APHM, INSERM, INRAe, C2VN, Marseille, France.

ORCID-Profile: Dominique Desprez, Mathieu Fiore, Roseline d'Oiron, Marie-Christine Alessi

Zitieren

APA

Saultier, P., Grino, M., Falaise, C., Voisin, S., Lavenu-Bombled, C., Ibrahim-Kosta, M., Petit, A., Boutroux, H., Desprez, D., Fiore, M., d'Oiron, R., & Alessi, M. C. (2025). Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review. Haemophilia. https://doi.org/10.1111/hae.15130

Vancouver

Saultier P, Grino M, Falaise C, Voisin S, Lavenu-Bombled C, Ibrahim-Kosta M, et al. Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review. Haemophilia. 2025. doi:10.1111/hae.15130

BibTeX
@article{Saultier2025,
  author = {Saultier, Paul and Grino, Michel and Falaise, Céline and Voisin, Sophie and Lavenu-Bombled, Cécile and Ibrahim-Kosta, Manal and Petit, Audrey and Boutroux, Hélène and Desprez, Dominique and Fiore, Mathieu and d'Oiron, Roseline and Alessi, Marie-Christine},
  title = {Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.15130}
}
Kostenlos starten →